1Rodgers JE;Patterson JH.Angiotensin Ⅱ-receptor blockers: clinical relevance and therapeutic role,2001(08).
2Yusuf S;Sleight P;Pogue J.Effects of an angiotensin-converting-enzyme inhibitor, ramipril,on cardiovascular events in high-risk patients[J],2000(03).
3Unger T;Azizi M;Belz GG.Blocking the tissue renin-angiotensin system:the future cornerstone of therapy[J](Suppl 2),2000.
4Bravo EL.Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease[J],2003(02).
5Allikmets K.Aliskiren (Speedel),2002(10).
6Nussberger J;Wuerzner G;Jensen C.Angiotensin Ⅱ suppression in humans by the orally active renin inhibitor aliskiren (SPP100):comparison with enalapril[J],2002(01).
7Mancia G;Failla M;Grappiolo A.Present and future role of combination treatment in hypertension[J](Suppl 2),1998.
8Anon.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT),2002.
9Anon Major cardiovascular events in hypertensive patients randomized to doxazosin vschlorthalidone.The antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT),2000.
10Oparil S.Comparative antihypertensive efficacy of olmesartan:comparison with other angiotensin Ⅱ receptor antagonists[J](Suppl 2),2002.
